0001213900-26-041604
SEC filingOptimizeRx Corporation appointed Mary Varghese Presti as an independent director to its Board effective April 3, 2026, expanding the Board to seven members and appointing her to the Audit Committee, with compensation including $45,000 annual cash retainer, $175,000 annual equity grant, and $10,000 Audit Committee retainer.
The appointment of Mary Varghese Presti as an independent director marks a targeted enhancement to OptimizeRx’s governance structure, supporting its stated objective of board refreshment and strategic expansion. Her background as Corporate Vice President and Chief Operating Officer of Microsoft’s Health & Life Sciences organization brings deep expertise in scaling AI-powered healthcare platforms, commercializing health technology, and leading post-acquisition integration—areas directly relevant to OptimizeRx’s stated strategy of evolving into a more integrated, product-led platform with increasing recurring revenue. The Board’s decision to expand from six to seven members and assign her to the Audit Committee signals intent to strengthen both strategic oversight and financial governance rigor. Compensation terms are fully aligned with the Company’s pre-existing non-employee director program, indicating no special arrangements or incremental cost structure beyond standard practice. While director appointments are routine governance events, the specific profile and functional relevance of Varghese Presti’s experience—particularly in AI-driven clinical and operational transformation—elevates this beyond procedural refreshment and positions her as a strategic advisor during a period of rapid technological change in the healthcare engagement space.